Sinopharm Group Co. Ltd. released its Monthly Return for Equity Issuer for the period ended 31 August 2026, confirming a stable capital structure with no changes in either authorised or issued share capital.

Authorised / Registered Share Capital • H Shares: 1.34 billion shares at RMB 1 par value, unchanged month-on-month. • Domestic Shares: 1.78 billion shares at RMB 1 par value, also unchanged. • Combined authorised/registered share capital: 3.12 billion shares.

Issued Shares and Treasury Position • H-share issuance remained at 1.34 billion shares, with no treasury shares held. • Domestic-share issuance stood at 1.78 billion shares, likewise with no treasury shares. • No share repurchases, cancellations, or new issuances were recorded during the month. • No warrants, options, convertibles, or other equity-linked instruments were outstanding or exercised.

Public Float Sinopharm confirmed compliance with the Main Board Rule 13.32D(1) requirement that at least 25% of its H-share class remains in public hands.

Additional Notes The company did not report any Hong Kong Depositary Receipts or other share movements. The filing was submitted on 4 September 2026 by Company Secretary Wu Yijian.